232 related articles for article (PubMed ID: 34112738)
1. Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity.
Legscha KJ; Antunes Ferreira E; Chamoun A; Lang A; Awwad MHS; Ton GNHQ; Galetzka D; Guezguez B; Hundemer M; Bourdon JC; Munder M; Theobald M; Echchannaoui H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34112738
[TBL] [Abstract][Full Text] [Related]
2. Enhancing chimeric antigen receptor T cell therapy by modulating the p53 signaling network with Δ133p53α.
Roselle C; Horikawa I; Chen L; Kelly AR; Gonzales D; Da T; Wellhausen N; Rommel PC; Baker D; Suhoski M; Scholler J; O'Connor RS; Young RM; Harris CC; June CH
Proc Natl Acad Sci U S A; 2024 Mar; 121(10):e2317735121. PubMed ID: 38408246
[TBL] [Abstract][Full Text] [Related]
3. Expanded antigen-experienced CD160
Bozorgmehr N; Okoye I; Oyegbami O; Xu L; Fontaine A; Cox-Kennett N; Larratt LM; Hnatiuk M; Fagarasanu A; Brandwein J; Peters AC; Elahi S
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931471
[TBL] [Abstract][Full Text] [Related]
4. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
5. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
6. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
7. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
[TBL] [Abstract][Full Text] [Related]
8. Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors.
Dotsu Y; Muraoka D; Ogo N; Sonoda Y; Yasui K; Yamaguchi H; Yagita H; Mukae H; Asai A; Ikeda H
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115364
[TBL] [Abstract][Full Text] [Related]
9. The Evolving Role of CD8
Huff WX; Kwon JH; Henriquez M; Fetcko K; Dey M
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181772
[TBL] [Abstract][Full Text] [Related]
10. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
12. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
[TBL] [Abstract][Full Text] [Related]
13. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
14. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
Kalbasi A; Shrimali RK; Chinnasamy D; Rosenberg SA
J Immunother; 2010 Sep; 33(7):672-83. PubMed ID: 20664359
[TBL] [Abstract][Full Text] [Related]
15. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Zelle-Rieser C; Thangavadivel S; Biedermann R; Brunner A; Stoitzner P; Willenbacher E; Greil R; Jöhrer K
J Hematol Oncol; 2016 Nov; 9(1):116. PubMed ID: 27809856
[TBL] [Abstract][Full Text] [Related]
16. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
17. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.
Ye J; Ma C; Hsueh EC; Dou J; Mo W; Liu S; Han B; Huang Y; Zhang Y; Varvares MA; Hoft DF; Peng G
EMBO Mol Med; 2014 Oct; 6(10):1294-311. PubMed ID: 25231413
[TBL] [Abstract][Full Text] [Related]
18. Enhancing adoptive T cell immunotherapy with microRNA therapeutics.
Ji Y; Hocker JD; Gattinoni L
Semin Immunol; 2016 Feb; 28(1):45-53. PubMed ID: 26710685
[TBL] [Abstract][Full Text] [Related]
19. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice.
Zhang C; Lei L; Yang X; Ma K; Zheng H; Su Y; Jiao A; Wang X; Liu H; Zou Y; Shi L; Zhou X; Sun C; Hou Y; Xiao Z; Zhang L; Zhang B
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34642245
[TBL] [Abstract][Full Text] [Related]
20. TCR-engineered, customized, antitumor T cells for cancer immunotherapy: advantages and limitations.
Chhabra A
ScientificWorldJournal; 2011 Jan; 11():121-9. PubMed ID: 21218269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
